Media Summary: What happens to subsequent treatment lines when you selectively swap out an endocrine backbone at the first sign of an ESR1 ... In this segment, Dr. Eleonora Teplinsky unpacks major insights from ASCO, focusing on the Can we act on endocrine resistance before it shows up on scans? In
Serena 6 Design And Future - Detailed Analysis & Overview
What happens to subsequent treatment lines when you selectively swap out an endocrine backbone at the first sign of an ESR1 ... In this segment, Dr. Eleonora Teplinsky unpacks major insights from ASCO, focusing on the Can we act on endocrine resistance before it shows up on scans? In Can earlier detection of ESR1 mutations change the treatment trajectory in metastatic HR+/HER2- breast cancer? Drs. Jason ... First Look With ASCO Daily News presents Dr. Julie Gralow, ASCO's chief medical officer, on the results of the Is delaying chemotherapy just as important as extending survival? Drs. Hallmeyer and Gradishar break down how
Can early intervention change the course of metastatic HR+ breast cancer? In this expert discussion, Dr. Seth Wander and Dr. Jason Mouabbi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, gives an overview of key studies in ... Can a proactive switch at the time of molecular progression truly extend the long-term benefit of endocrine therapy? Drs. Jason ... Should endocrine therapy change before radiographic progression in ESR1-mutant metastatic breast cancer? Drs. Neil Iyengar ... Why does staying on first-line therapy longer matter? Dr. Seth Wander and Dr. Erica Mayer discuss how early intervention in ...
